BioCryst Pharma (BCRX) Subject to Prise Target Raise by Wedbush
On March 2, Wedbush analyst Laura Chico increased the firm’s price target on BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to $22 from $21. The analyst maintained her Outperform rating on the stock.





